Alzheimer's disease (AD) is a neurodegenerative condition resulting in significant neuronal loss and a decline in the function of various neurotransmitter systems (Casey, Antimisiaris & O'Brien, 2010) . These brain changes lead to cognitive dysfunction, neuropsychiatric symptoms, and difficulties with activities of daily living (ADLs; Burns & Iliffe, 2009 ). Memory loss is commonly the first symptom in AD manifesting insidiously as an inability to form new memories (Burns & Iliffe, 2009) . Dementia due to AD is formally diagnosed when cognitive or behavioral symptoms represent a significant decline from previous levels of functioning and interfere significantly with performance on ADLs such as working or personal responsibilities (McKhann et al., 2011) .
Given that the symptoms of AD result from brain changes and neurotransmitter deficiencies, pharmacological treatments that attempt to ameliorate the cognitive symptoms have been investigated (Casey et al., 2010; Citron, 2010) . However, pharmacological treatment has not been shown to have a clinically relevant effect despite statistically significant effects on clinical trials (Lanctôt, Rajaram, & Herrmann, 2009 ). Thus, nonpharmacological treatments tailored to address cognitive, behavioral, and psychological symptoms have received much attention in recent years (Brodaty & Arasaratnam, 2012; Gardette, Coley, & Andrieu, 2010) .
Cognitive intervention is an alternative to pharmacological treatment for people with AD. There are three types of cognitive intervention: cognitive training, cognitive stimulation, and cogni-tive rehabilitation. Cognitive stimulation involves engagement in group activities such as conversation aimed at enhancing cognitive and social functioning (Clare, 2003) . Cognitive training involves the use of guided standardized tasks through which people with AD are taught theory-based strategies and abilities to improve their cognitive functioning. This type of intervention can be conducted both individually as well as in a group and can also include computer-based training (Ballard, Khan, Clack, & Corbett, 2011; Kurz et al., 2012) , and varying difficulty levels are offered based on the severity of cognitive impairment. Cognitive rehabilitation (also referred to as cognitive remediation), unlike cognitive training and cognitive stimulation programs, aims to develop and implement cognitive strategies applied to specific ADLs through the use of task-specific techniques and external supports (Grandmaison & Simard, 2003; Kurz et al., 2012) . Through cognitive rehabilitation programs, people with AD can be taught face-name associations, routes, the use of an external memory aid, or even ameliorate behavioral difficulties (Clare, 2003) .
The efficacy of cognitive interventions for AD has been examined recently through three excellent meta-analyses (Clare, Woods, Moniz Cook, Orrel, & Spector, 2003; Olazarán et al., 2010; Sitzer, Twamley, & Jeste, 2006) and two successive updates (Bahar-Fuchs, Clare, & Woods, 2013; Clare & Woods, 2008) . The conclusions of these three meta-analyses are quite different and even contradictory. After reviewing 11 randomized controlled trials (RCTs), Bahar-Fuchs et al. (2013) concluded that "no positive or adverse effects for cognitive training were detected" (p. 25). Sitzer et al. (2006) concluded that cognitive training produced large effects on verbal memory after reviewing 19 controlled trials. After reviewing 179 studies, Olazarán et al. (2010) concluded that there is a Grade B (consistent low-quality RCTs) recommendation for cognitive training and cognitive stimulation to improve cognition (e.g., memory) in people with dementia. So why are the results from these studies, apparently investigating the same construct, so different?
One explanation might be the methodology used to conduct the meta-analysis and calculate ESs. Sitzer et al. (2006) and Bahar-Fuchs et al. (2013) calculated ESs using change scores and change standard deviations, but then calculated ESs with raw scores for part of the outcomes analyzed. In contrast, Olazarán et al. (2010) calculated ESs using change scores and odds ratios. When ESs are calculated using change scores, both pre-and posttest standard deviations are included in the formula (Borenstein, Hedges, Higgins, & Rothstein, 2009 ). However, when ESs are calculated using raw scores, only pretest standard deviations are used, so combining ESs derived from both methods is incompatible. Combining preand posttest standard deviations will produce comparable ESs when the variability of scores is constant across time periods (Morris & DeShon, 2002) , which is unlikely when a treatment group is compared to a group with different treatments or no treatment at all and a Group ϫ Time interaction is expected.
Another explanation for the varying findings is the correlation between ESs within each study used to calculate the average ES, which is twofold. On the one hand, the pre/post correlation of each individual measure is needed to calculate the repeated measures ES. On the other hand, studies analyzing the effect of a treatment include both multiple groups and multiple outcomes, which means that ESs reported are not independent. Bahar-Fuchs et al. (2013) assumed that the correlation between pre-and posttest scores was zero, whereas Sitzer et al. (2006) and Olazarán et al. (2010) did not report how they controlled for the pre/post correlation. Statistical analyses exist that allow to analyzing the effects of correlational coefficients on ESs and to modeling for covariance structures (Tanner-Smith & Tipton, 2014) , so analyzing dependent ESs as if they were independent may lead to incorrect conclusions.
In summary, the three meta-analyses relied on incompatible statistical measures to calculate and compare ESs, which makes their results questionable. As Cooper (2010) stated, combining different outcome measures may obscure "important distinctions among the outcomes and might have been misleading" (p. 150). Furthermore, Higgins and Green (2008) added that the use of a meta-analysis may not be meaningful if the treatments are so different that an effect estimate cannot be interpreted in any specific context.
This study, then, has three main goals. First, it will provide a review of the literature regarding the efficacy of cognitive interventions to improve cognition in AD. Special attention will be given to the verbal memory domain as memory impairment is the initial and most prominent cognitive deficit in AD, and the amnestic-type is the most common presentation of AD dementia symptoms (McKhann et al., 2011) . Second, our study will conduct a meta-analysis of these interventions with adequate statistical methods to reduce the impact of bias. Finally, and as the main goal of this study, we hope to provide a different approach to metaanalysis by analyzing ESs according to specific characteristics of each study design that might potentially affect results in research studies (Higgins & Green, 2008) : randomization, independence of evaluators, and control condition. Even if outcomes from primary studies are scaled in the same metric (e.g., raw score metric) in a meta-analysis, different ESs would be expected between random and nonrandom studies, between studies with or without blind assessors or between studies with different control groups (e.g., cognitive plus pharma vs. placebo). For example, higher ESs are expected when a cognitive intervention is compared to a drug-only group because "comparing two active interventions is likely to reduce effect size" (Olazarán et al., 2010, p. 172 ) and because drug therapy has limited effects on cognition (Birks & Harvey, 2006; Raina et al., 2008) .
Based on previous reviews, we expected to find low to medium ESs on cognitive and functional outcomes and hypothesized that studies without control for potential sources of bias would provide higher ESs compared to controlled studies.
Inclusion Criteria
To be included in the meta-analysis, studies had to (a) have a population with AD in the experimental group; (b) have at least one outcome, either primary or secondary, related to verbal memory and/or cognition; (c) be cohort studies where the control group receives the same treatment, an alternate treatment, or no treatment at all compared to the experimental group; (d) be published in English, because excluding studies published in languages other than English has little effect on treatment effect estimates (Jüni, Holenstein, Sterne, Bartlett, & Egger, 2002; Morrison et al., 2012) ; (e) include participants meeting a probable or possible diagnosis of AD according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al., 1984; McKhann et al., 2011) ; and (f) report pre-and posttest means and standard deviations for both treatment and control groups. Each paper was evaluated for inclusion independently by the first two authors using the criteria stated above. In case of a discrepancy, the third author reviewed the paper and decided for inclusion. This happened only for the study by Cipriani, Bianchetti, and Trabucchi (2006) , which included only participants with mild cognitive impairment (MCI) in the control group. It was finally included because the experimental group was comprised of people with AD.
Methodological Quality Assessment
An evaluation checklist designed to include the main points regarding quality of research methodology from the document "Strengthening the Reporting of Observational Epidemiological Studies: STROBE Statement" (Vandenbroucke et al., 2007 ; see Appendix A), along with the specific outcomes for each study, were used to perform separate meta-analyses with a reliable and standardized research methodology. As in the case of the criteria for inclusion, the methodological quality of each paper was evaluated independently by the first two authors, and discrepancy was resolved by the third author.
Correlational Meta-Analysis

Statistical Analysis
Average r ES calculation. Because the formula for the ES variance includes the pre/post correlation, we contacted the authors and requested the pre/post correlation on each outcome from the primary studies. We meta-analyzed the available correlations using the Hedges and colleagues' random effects methodology described by Field (2001) This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. Based on the findings of the correlational meta-analysis, we then performed a sensitivity analysis using correlational values in ranges of .10 to investigate their impact on the average ESs. As shown in Appendix C, the average ES remained constant across different correlational values, with a slightly difference of .03. The average ES using the real correlations compared to the average ES using the average r changed from 0.29 to 0.27. Based on these results, we calculated the variance of ESs from both the experimental and control groups using the average correlational ES for each group, respectively.
Effect size calculation. ESs were calculated with the formula for independent groups pre/posttest (IGPP) based on raw scores (Morris, 2008; Morris & DeShon, 2002) , which includes the standard deviation of the pretest as an unbiased estimate of the variance. ESs for each independent group were corrected using the bias function formula and weighted by the reciprocal of its sampling variance (Morris & DeShon, 2002) , which was calculated with the average r separately for the experimental and control groups. All these statistics were calculated using Microsoft Excel 2007. Although there are different options for calculating ESs in pre/post designs, the IGPP design was selected for three reasons: (a) it provides separate ESs for experimental and control groups, so it is possible to observe ESs in groups with different control interventions; (b) it includes the pre/post correlations of each separate group for the variance calculations, not the pooled pre/post correlation across groups; and (c) the observed variance of the IGPP design does not differ from the theoretical variance more than 3% under most conditions (Morris, 2008) .
To compare our results with the three previous meta-analyses, we calculated the average ES for the following:
• The Mini-Mental State Examination (MMSE; Folstein, Folstein, & McHugh, 1975) • Memory outcomes: word-list tasks (Rey Auditory Verbal Learning Test, Rey, 1964; Hopkins Verbal Learning Test, Benedict, Schretlen, Groninger, & Brandt, 1998 ; selective reminding test, Kessler, Denzler, & Moskowitsch, 1988 ), a story recall task (brief story recall, Novelli et al., 1986; logical memory test, Wechsler, 1987; prose memory, Capitani, Della Sala, Laiacona, Marchetti, & Spinnler, 1994) , and a face-name association task and a memory battery (Rivermead Behavioral Memory Test, Wilson, Baddeley, & Cockburn, 2003) . Word-list tasks and story recall tasks were analyzed separately where possible. • Basic ADLs (Katz Index for Activities of Daily Living, Katz, Ford, Moskowitz, Jackson, & Jaffe, 1963 ; Bayer Activities of Daily Living Scale, Hindmarch, Lehfeld, de Jongh, & Erzigkeit, 1998 ; Functional Living Skills Assessment, Farina et al., 1999) .
• The Instrumental ADL Questionnaire (IADL; Lawton & Brody, 1969 & Linn, 1982) . (Heiss et al., 1993; Heiss et al., 1994; Davis, Massman, & Doody, 2001) , educational information (Cahn-Weiner, Malloy, Rebok, & Ott, 2003) , recreational activities (Farina et al., 2006; Bergamaschi et al., 2013) , semistructured intervention on current affairs and relevant events (Galante, Venturini, & Fiaccadori, 2007) , muscle relaxation 
As in correlational meta-analysis, homogeneity of ESs was calculated using Hedges' Q (Morris, 2008) and the I 2 statistic (Higgins & Thompson, 2002) . In Hedges' Q, the null hypothesis is that all the studies have a common ES. The I 2 provides a measure of the total variation in ESs that is due to the heterogeneity between studies. Percentages for low, moderate, and high heterogeneity are 20%, 50%, and 70% respectively. Whenever I 2 yielded a negative result, it was expressed as 0% (Higgins, Thompson, Deeks, & Altman, 2003) .
As the same participants provided different ESs within each study, the robust variance estimator (RVE) for correlated ESs was applied (Hedges, Tipton, & Johnson, 2010; Tanner-Smith & Tipton, 2014) . The RVE provides an ES after the statistical dependency among ESs is accounted for. It provides both an unconditional ES and a multivariable metaregression model to test the This document is copyrighted by the American Psychological Association or one of its allied publishers.
This article is intended solely for the personal use of the individual user and is not to be disseminated broadly. 4 influence of moderators on ESs. We run the RVE for correlated effects using the SPSS macro developed by Tanner-Smith and Tipton (2014) . This estimation provides a beta coefficient that is equal to the unconditional mean ES across studies, and tests the hypothesis of b 0 with a t test with "number of studiesparameters" degrees of freedom (in this case, k -1). To calculate the RVE, the assumed correlation between all pairs of ES within studies must be specified. Tanner-Smith and Tipton (2014) suggest to use an average correlation found in one or more studies, although the cost of choosing an inappropriate value is negligible because it does not affect the precision of the confidence intervals, t test or statistical inferences. We, therefore, used the average correlation within the experimental groups (r ϭ .70). The same macro was used to test the effect of moderators. As different designs and different populations were used in each study, the random effects model was applied (Borenstein, Hedges, Higgins, & Rothstein, 2009) , which assumes that each ES is a sample of a distribution of possible ES and includes the variance within and the variance between studies in its calculation.
We calculated the power of each unconditional ES using the formula described by Hedges and Pigott (2001) for the hypothesis ES ϭ 0. This formula uses the z statistic and the normal cumulative distribution. For a two-tailed test, Power
The symbol ⌽ represents the standard normal cumulative distribution function and Z ‫ء‬ is calculated with the formula ES ⁄ ͙Var * with the random effects variance in the denominator. The results of the unconditional ESs will be presented except when the robust variance estimator showed that a significantly different from zero ES turned out to be nonsignificant or vice versa. Power of tests from the RVE could not be computed because, to date, there has not been any work on computing power with RVE (Elizabeth Tipton, personal communication, October 10, 2015). Power was computed for 23 out of 35 tests.
To test whether the moderators were highly collinear with one another, we created a binary variable for each study (0 ϭ no, 1 ϭ yes) within each of the moderator variables and produced a correlation matrix of the moderator variables at study level (n ϭ 19) so as to give an overview of the intercorrelation between moderators (e.g., correlation between random and nonrandom studies is Ϫ1; if all the random studies had a placebo control group, then the correlation between these two moderators would be 1). Results are presented in Appendix D.
The significance level was set at ␣ Ͻ .01 for two reasons: first, because of the high number of tests for statistical significance; second, because of the small number of studies included for calculating ESs and for estimating the metaregression coefficient. Tanner-Smith and Tipton (2014) suggest using an alpha level p Ͻ .01 or p Ͻ .001 when using the robust variance estimation with 10 -40 studies.
Results
Characteristics and Quality of Studies
Nineteen studies with 812 participants (N treatment ϭ 356; N Control ϭ 456) were meta-analyzed. For a detailed description of each study, its participants, duration and the type of measures used as well as the outcomes obtained, see Table 1 . Table 2 provides a summary of the characteristics of each study defined as potential biases. The median number of biases was 7 (M ϭ 6.16 Ϯ 2.22), with a range from 2 to 9. The most frequent potential bias was the absence of a double-blind design, followed by the lack of exclusion criteria and the absence of a detailed explanation of the interventions. Nine studies compared a treatment intervention with a cognitive stimulation control condition, 10 studies compared a treatment intervention with a placebo control condition, and six studies compared a treatment intervention with cognitive plus pharma, pharma-only control condition, or no treatment at all.
Effect Size Comparison
Eighty-seven measures were identified in the 19 studies (see Figure 2 ). Sixty-seven (77%) were cognitive measures and 20 (23%) were functional measures. The average ES for all research outcomes together was small and significantly different from zero (ES ϭ 0.30, var ϭ .00, 99% CI [0.17, 0.44], z ϭ 5.77, p ϭ .000) with high heterogeneity between ESs across studies (I 2 ϭ 76%). This average ES was taken as a general measure of treatment effects to give an overview of the variability of ESs. Separate ESs for experimental and control groups are shown in Appendix E.
The MMSE ( Tables 4 and 5 show ESs when studies were combined based on control for randomization, independence of evaluators, and control intervention respectively.
Moderator Analyses
Randomization. The MMSE ES was small-to-medium and not different from zero in both randomized (k ϭ 9; ES ϭ 0.59, SE ϭ .26, 99% CI [Ϫ0.27, 1.46], t ϭ 2.31, p ϭ .050) and nonrandomized studies (k ϭ 6; ES ϭ 0.25, var ϭ .02, 99% CI [Ϫ0.10, 0.59], z ϭ 1.86, p ϭ .063). ES from memory outcomes was small and different from zero in randomized studies (k ϭ 11; ES ϭ 0.29, var ϭ .01, 99% CI [0.09, 0.49], z ϭ 3.72, p Ͻ .001) This document is copyrighted by the American Psychological Association or one of its allied publishers.
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OLTRA-CUCARELLA ET AL. Metaregression analyses showed no effect of the control condition in any of the variables analyzed (all p Ͼ .01).
Conclusions
This meta-analysis intended to extend the results provided by previous meta-analyses regarding the effectiveness of cognitive interventions for AD by analyzing ESs with a different methodology: calculating ESs in a common metric, calculating the average ES using metaregression for correlated ESs and analyzing potential sources of biases as moderator variables.
When the ESs of all the selected studies were combined to get an average ES, the results showed low efficacy and high heterogeneity on ESs. The effects of interventions on cognitive and functional outcomes were negligible to low. Mean ESs for measures of general cognitive functioning were higher than those reported by Bahar-Fuchs et al. (2013; ES ϭ 0.10) and similar to and one with participants with AD and MCI (Loewenstein et al., 2004) .
Regarding the ADLs, we found a higher ES than the one reported by Bahar-Fuchs et al. (2013; ES ϭ 0.00) and smaller than the one reported by Olazarán et al. (2010;  ES ϭ 0.37-0.41) and Sitzer et al. (2006;  ES ϭ 0.32-0.75). As heterogeneity among functional ESs was low to moderate (I 2 ϭ 0.00 -0.50), and mean ESs for functional outcomes were consistent across methodological designs (ES ϭ Ϫ0.04 -0.29), our results suggest that the effect of cognitive stimulation on functional outcomes for AD is low, in line with other findings regarding the absence of transfer to untrained situations. As dementia is diagnosed when cognitive impairment interferes with ADLs, our results highlight the need to develop cognitive interventions that provide persons with AD with strategies to cope with ADLs and further suggest that the kind of cognitive interventions published to date may be ineffective to improve memory, cognition, and functionality.
Several factors could explain our results. First, measures of general cognitive outcome are too broad and do not focus on the outcome of interest (e.g., the MMSE for assessing verbal memory). A measure of general cognitive functioning, thus, would have limited usefulness as it is likely unrelated-or only tangentially related-to what has been trained during the intervention. For example, Loewenstein et al. (2004) and Davis et al. (2001) trained their participants in a facename association task, whereas Giordano et al. (2010) trained their participants using reality orientation therapy. It is unlikely that a measure of general cognitive functioning can reliably identify any improvement in memory regarding face-name association, even though the participant identifies correctly all the items included in the intervention task. In the case where reality orientation therapy is effective and the participants improve their time orientation, it is likely that some improvements in measures such as the MMSE are evident, but its functional correlate with ADLs is uncertain. Thus, we suggest that the efficacy of interventions be measured through the achievement of personalized goals rather than through the use of general tests such as the MMSE or the ADAS-Cog subscale to truly impact the needs of people with AD dementia. Some examples of this type of intervention were carried out by and Zanetti et al. (2001) . performed an intervention focused on relevant goals to the individual and found that participants who received personalized intervention rated higher on both performance and satisfaction after intervention, whereas control groups did not show any significant change. Zanetti et al. (2001) trained their participants in basic and instrumental ADLs and analyzed the impact of the intervention through the decrease in the time needed to perform the task.
A possible explanation for the absence of significant functional improvements is that none of the studies in the meta-analysis included a treatment group trained by an occupational therapist in specific ADLs. As occupational therapists are skilled in improving ADLs through meaningful activity training programs including the preferences, interests, and the strengths of people with dementia (National Collaborating Centre for Mental Health, 2007), any rehabilitation program seeking to improve functionality and independence must include these health workers within the professional staff. The only work that included occupational therapists was the one by Fernández-Calvo et al. (2015) , but their specific intervention on ADLs was not detailed. If the rationale for a memory intervention is that any improvement in cognition will transfer to untrained situations such as ADLs, then probably nonsignificant results are likely to be reported because of a lack of transfer to untrained situations (McDaniel & Bugg, 2012) .
Another explanation could be the limited sensitivity of functional scales and questionnaires in general to small although significant changes for individual participants. The use of group Table 1   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  %   Groups  4  4  3  2  4  3  2  2  3  3  2  2  3  2  2  2  2 
.63 ⌺ bias 9 7 7 4 3 9 7 9 5 7 8 5 3 8 8 4 5 2 7
Note. Y ϭ yes; N ϭ no (bias).
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COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS means instead of single-subject data could mask clinically significant changes that cannot be observed in standardized tests and questionnaires. The use of data from a group where no improvements are found will suggest that the intervention is not effective (which is the case in this work); however, analyzing the data from individuals within a group may provide insights about the individual's characteristics related to the efficacy of such intervention. Given the importance of functional ADLs, we consider that future works should compare a cognitive intervention only to an intervention combining cognitive ϩ functional activities focusing on training participants in ADLs (e.g., preparing meals) and significant relevant goals (e.g., finding personal belongings, dressing), and measure their improvement using outcomes such as the time required to perform each task, the number of errors on each task, the number and type of external help needed, or the satisfaction derived from performing those tasks (Clare, Evans, Parkinson, Woods, & Linden 2011; Zanetti et al., 2001) . It is important to note that we do not suggest that interventions must be carried out according to the predefined outcome measure. Rather, outcomes specifically related to trained situations should be selected to measure the efficacy of any given intervention before even initiating it. Our hypothesis is that ESs will become medium to large for variables related to trained situations and will remain low for measures such as the MMSE or the IADL questionnaire.
Differences in ES Due to Methodological Bias
Contrary to our expectations, we could not find differences in ESs for cognitive or functional outcomes when participants are randomly assigned to groups, participants are assessed by personnel blinded to group allocation or when a treatment intervention is compared to another cognitive intervention, a placebo intervention or an alternate intervention (cognitive plus pharma, pharma-only, or no treatment at all). Olazarán et al. (2010) found that the effects of multicomponent interventions were similar to the effects obtained by drug therapy and suggested that these interventions should be complementary. Nevertheless, one would expect a higher ES when the cognitive intervention is compared to a drug-only group (Birks & Harvey, 2006; Olazarán et al., 2010; Raina et al., 2008) . According to these findings, there would be no reason for recommending cognitive interventions or other kind of interventions such as social support or mental stimulation over pharmacotherapy, as ESs in the latter case were not different from zero. However, it cannot be concluded that there are no beneficial effects of cognitive intervention over pharmacotherapy alone or in combination with cognitive stimulation because the small number of studies and outcomes reduced the power to find significant effects.
Contrary to our expectations, studies that did not control for bias did not show higher ESs. Overall, average ESs with and without control for bias showed that the effects of the interventions on measures of general cognitive functioning were similar to those on functional outcomes, which supports the conclusions of others who question the efficacy of cognitive training as it has been performed in previous research (Bahar-Fuchs et al., 2013; McDaniel & Bugg, 2012) . These results are in line with other meta-analyses assessing cognitive interventions in other populations with neurologic diseases such as multiple sclerosis (Magalhães et al., 2014) or brain injury (Rohling, Faust, Beverly, & Demakis, 2009) , which found no significant effects of interventions on memory. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
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Number of outcomes 
27.56 (14) 5.72 (3) 8.28 (4) 5.39 (5) 6.31 (5) 23.18 (13) 13.90 (10) 8.25 (7) 5.76 (6 Table 1 1-3, 10-12, 16-18 4, 6, 8, 9, 14, 15 1-3, 5, 7, 11, 13, 16-18 4, 8, 9 5, 7, 12, 16-19 4, 8, 9, 14 3, 4, 9, 12, 15-18 1, 2, 6, 8, 10, 11, 14 3-5, 7, 9, 12, 13, 16-18 1, 2, 8, 11 4, 5, 7, 9, 12, 16-19 8, 14 Sample size
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COGNITIVE INTERVENTIONS IN AD: META-ANALYSIS
This work has, notwithstanding, several limitations. One of the main caveats is that some relevant work in the area of cognitive interventions on AD was not included because it failed to meet our requirements for diagnostic criteria or pre/post statistics (Gaitán et al., 2013; Kurz et al., 2012; Metitieri et al., 2001; Olazarán et al., 2004; Onder et al., 2005; Simmons-Stern, Budson, & Ally, 2010; Zanetti et al., 2001) . All the participants met the Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association's criteria for AD, which are biased toward memory impairments. However, there exist atypical AD presentations such as focal posterior cortical atrophy or progressive aphasia in which episodic memory could either be spared during the initial phases (Galton, Patterson, Xuereb, & Hodges, 2000) or be so pronounced that suggest a critical diagnostic feature (Lambon Ralph, Patterson, Graham, Dawson, & Hodges, 2003) . In the absence of a detailed explanation of complementary exams (e.g., magentic resonance images, biomarkers), the different characteristics of persons diagnosed with AD could account for some of the variability in the effects of treatment. We recommend that future research use diagnostic criteria including both biomarkers and neuropsychological testing specifically designed for target populations, thus increasing sensitivity and specificity (Becker, Boller, Lopez, Saxton, & McGonigle, 1994; Lopez, McDade, Riverol, & Becker, 2011) instead of using more general criteria such as those included in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and Fourth Edition Text Revision (American Psychiatric Association, 1994, 2000) .
Another limitation to this study, which could explain the failure to find any significant effect, is the reduction of power due to the small number of outcomes and studies. For example, when comparing ESs for cognitive outcomes between random and nonrandom studies, we could only compare 37 variables from 13 random studies with seven variables from five nonrandom studies. We cannot conclude that there are no significant differences between ESs, because we had not enough power to detect such differences (Hedges & Pigott, 2001) . The average power of our analyses was 0.27 (median ϭ 0.23), which limits our conclusions. This prevents us from asserting that ESs are not different from zero or that there are no differences in ESs when studies are compared according to methodological biases; rather, our analyses were underpowered to detect such an affect. However, if data from studies with lower risk of bias (randomization and independent assessors) are taken as closer to the real ES, our results indicate that the average ES is small for cognitive (ES ϭ 0.44) and functional (ES ϭ 0.22) outcomes.
Including underpowered studies in meta-analysis is not uncommon. Turner, Bird, and Higgins (2013) found that in 70% of a Cochrane meta-analyses review all studies were underpowered, whereas 66% of the meta-analyses themselves were underpowered. As power in random effects model is affected by both the number of studies and the variance between studies (Cohn & Becker, 2003) , which changes as a function of sample size, additional studies with larger sample sizes are needed to more accurately meta-analyze the efficacy of cognitive interventions in AD according to moderator variables and powered studies.
We cannot rule out the possibility that other sources of bias affected the ESs. For example, while the majority of studies compared at least two groups of AD participants, Hofmann et al. Regarding the pharmacological interventions, the majority of studies in this meta-analysis included participants treated with stable doses of cholinesterase inhibitors (donepezil or memantine), whereas Farina et al. (2002) and Cahn-Weiner et al. (2003) did not report any pharmacological treatment, Jelcic et al. (2012) and Hofmann et al. (2003) included participants with no pharmacological treatment, and Heiss et al. (1993; Heiss et al. 1994 ) included a group with dietary supplement and other group with a drug similar to vitamin B 6 . Because pharmacological treatments used to enhance cognition in AD have shown small effects on cognitive and functional outcomes (Raina et al., 2008) , we cannot rule out that the ESs reported here are a consequence of these interventions. It is worth noting that ESs for cognitive (ES ϭ 0.42) and functional (ES ϭ 0.19) variables from studies in which patients were taking cholinesterase inhibitors are still small and negligible, respectively. This is, to our knowledge, the first meta-analysis on cognitive interventions in AD that calculates ESs controlling for their intercorrelations and measuring the effects of moderators such as the comparison groups. The main finding is that ESs for functional and cognitive outcomes were negligible to low and that did not differ when potential sources of bias were controlled (e.g., MMSE or functional ESs), an issue that future research should take into account when reporting findings. As pointed out by a reviewer, some works This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
14 compared a cognitive training group with a control group receiving cognitive stimulation, whereas other studies compared an experimental group receiving cognitive stimulation with a control group receiving placebo or pharma only. Thus, cognitive stimulation is used as an experimental intervention in some studies and as a control intervention in some others. This type of comparisons will not estimate the same ES parameter and limits the generalization of our results. Our moderator analyses showed no differences in ESs according to the control group intervention, probably due to power issues, but further research is needed to clarify whether cognitive interventions are more effective than pharma only or placebo, or even differently effective between each other (e.g., cognitive training vs. cognitive stimulation). We suggest that interventions should focus on personalized goals and should include measures related to trained situations instead of or in addition to standardized outcomes.
Formulas for Meta-Analysis on Means
ES in the experimental group:
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